Full Fed. Circ. Won't Take Up Biogen Appeal Over MS Drug
The Federal Circuit on Friday denied a request by Biogen to revisit a panel decision that revived a jury verdict invalidating claims of a patent covering its blockbuster multiple sclerosis treatment...To view the full article, register now.
Already a subscriber? Click here to view full article